China Resources Pharmaceutical Group Ltd.
3320
Rank in Stocks
#4326
China Resources Pharmaceutical Group Limited, an investment holding company,... China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
Share Price
$0.57950582
Market Cap
$3.64B
Change (1 day)
-2.69%
Change (1 year)
-5.97%
Country
HK
Trade China Resources Pharmaceutical Group Ltd. (3320)
Category
Healthcare
Revenue for China Resources Pharmaceutical Group Ltd. (3320)
Revenue in Jun 2026 TTM: $39.21B
According to China Resources Pharmaceutical Group Ltd. latest financial reports the company's current revenue (TTM) is $39.21B. In 2023 the company made a revenue of $34.63B an increase over the revenue in the year 2022 that was $32.52B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for China Resources Pharmaceutical Group Ltd. from 2013 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $39.21B | 11.04% |
| 2024 | $35.32B | 1.99% |
| 2023 | $34.63B | 6.47% |
| 2022 | $32.52B | 7.07% |
| 2021 | $30.37B | 17.51% |
| 2020 | $25.85B | -1.53% |
| 2019 | $26.25B | 8.39% |
| 2018 | $24.22B | 9.67% |
| 2017 | $22.08B | 9.26% |
| 2016 | $20.21B | 6.88% |
| 2015 | $18.91B | 8.04% |
| 2014 | $17.50B | 16.05% |
| 2013 | $15.08B | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $2.54B | -93.53% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $830.81M | -97.88% |
US
|
